我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
0
0 进行中
药物批准
629
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
FDA
Food and Drug Administration
- Sun Pharma voluntarily recalled a single batch of 675 vials of Doxorubicin Hydrochloride Liposome Injection after detecting glass particles during production. - The FDA warns that glass particles administered intravenously pose serious safety risks including blood vessel blockage and life-threatening blood clot events. - The recalled cancer treatment drug is used for ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma with an expiration date of May 31, 2027. - No adverse incidents have been reported to date, and Sun Pharma is arranging product returns and replacements through express overnight mail.
